SI-BONE, Inc. (NASDAQ:SIBN) Given Consensus Recommendation of "Buy" by Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

Several brokerages have commented on SIBN. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price target on shares of SI-BONE in a research note on Wednesday. Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley decreased their price target on shares of SI-BONE from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th.

SI-BONE Price Performance

Shares of SIBN traded up $0.27 during trading hours on Friday, reaching $12.56. 265,344 shares of the stock traded hands, compared to its average volume of 515,091. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE has a 52-week low of $11.70 and a 52-week high of $21.70. The company's 50-day moving average price is $13.72 and its two-hundred day moving average price is $14.22.

Insider Transactions at SI-BONE

In related news, CEO Laura Francis sold 10,048 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total value of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares of the company's stock, valued at $6,074,567.50. This represents a 2.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,937 shares of the business's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.60, for a total value of $49,606.20. Following the transaction, the insider now owns 228,554 shares of the company's stock, valued at $2,879,780.40. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,093 shares of company stock worth $299,558 in the last three months. Insiders own 3.90% of the company's stock.

Hedge Funds Weigh In On SI-BONE

Several hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in shares of SI-BONE by 1.5% during the second quarter. Rhumbline Advisers now owns 59,419 shares of the company's stock valued at $768,000 after purchasing an additional 852 shares during the period. Arizona State Retirement System boosted its position in SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after buying an additional 903 shares during the period. The Manufacturers Life Insurance Company grew its stake in SI-BONE by 7.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company's stock worth $205,000 after acquiring an additional 1,105 shares in the last quarter. FMR LLC increased its position in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of SI-BONE by 7.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company's stock valued at $336,000 after acquiring an additional 1,372 shares in the last quarter. Institutional investors own 98.11% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.